Advertisement
UK markets open in 6 minutes

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,228.75
    -157.12 (-0.96%)
     

  • CRUDE OIL

    83.70
    +0.97 (+1.17%)
     

  • GOLD FUTURES

    2,396.20
    -1.80 (-0.08%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • Bitcoin GBP

    51,738.21
    +2,654.57 (+5.41%)
     

  • CMC Crypto 200

    1,294.30
    -18.33 (-1.40%)
     

  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     

  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

AstraZeneca licenses inflammatory disease candidate to Allergan

Reuters - UK Focus

LONDON, Oct (HKSE: 3366-OL.HK - news) 3 (Reuters) - Britain's AstraZeneca (NYSE: AZN - news) said it had licensed a potential medicine for inflammatory diseases to Allergan (Frankfurt: A1W5NE - news) for an upfront payment of $250 million and potential additional payments of up to $1.27 billion.

AstraZeneca said the drug developed by its global biologics research and development arm MedImmune was being testing as a treatment for moderate-to-severe Crohn's disease and was ready to start trials for ulcerative colitis.

Amgen Inc (HKSE: 4332.HK - news) , which has been collaborating with MedImmune on developing the medicine, will receive a third of all payments and royalties received from Allergan, AstraZeneca (Swiss: AZN.SW - news) said on Monday.

(Reporting by Paul Sandle; editing by Sarah Young)